FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, not for consumption, not medicines. Research use policy
UK only · Prepared to order · approx. 7 days + Royal Mail Tracked 24 · No international shipping
Britpep
Basket 0
CJC-1295 (with DAC) 2 mg research peptide vial View vial label (BP-CJCDAC-2) →
Peptide · Lyophilised vial

CJC-1295 (with DAC)

Endocrine & receptor-signalling research peptides

GHRH(1–29) analogue carrying a Drug Affinity Complex (maleimido linker) for albumin conjugation, used in GHRH-receptor research.

Areas of research interest
£20.49 ex. VAT · per vial
Available

Prepared to order · approx. 7 days + Royal Mail Tracked 24

SKU BP-CJCDAC-2 · ≥99% (see COA) · Lyophilised powder

For laboratory research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic. Purchasers confirm research use, age 18+ and institutional/professional status at checkout. UK delivery only.
Data pending verification. Identity data in the specification below has been compiled for pre-launch and is awaiting verification against supplier documentation and batch COAs. Highlighted fields are unconfirmed.
Note: Salt form (e.g. acetate or TFA) and net peptide content to be confirmed from the supplier COA.

CJC-1295 (with DAC) overview

CJC-1295 with DAC is the tetra-substituted GHRH(1–29) analogue with a C-terminal lysine carrying a maleimidopropionyl linker, which lets it conjugate covalently to serum albumin. It is supplied as a lyophilised solid for in-vitro laboratory research.

Molecular formula
C₁₆₅H₂₆₉N₄₇O₄₆ [TO VERIFY against supplier COA]
Molecular weight
≈3647.2 g/mol [TO VERIFY against supplier COA]
Purity
≥99% (see COA)
Form
Lyophilised powder
Vial sizes & prices
2 mg – £20.49; 5 mg – £32.99; 10 mg – £65.99 (ex. VAT)
Delivery
UK only · prepared to order (approx. 7 days) then Royal Mail Tracked 24, £5.95

CJC-1295 (with DAC) research background

Early clinical

Evidence status: Findings summarised here come from preclinical research and small, early-phase human studies. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.

Established research

Peer-reviewed published findings, with references
Overview & discovery history
  • CJC-1295 (with DAC) is a modified GHRH(1–29) analogue carrying a 'drug affinity complex' (a maleimide-lysine linker), which binds covalently to serum albumin and extends its half-life. It was developed by ConjuChem [1][2].
Chemical identity
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(maleimidopropionyl)-NH₂ [TO VERIFY against supplier COA]
Molecular formula
C₁₆₅H₂₆₉N₄₇O₄₆ [TO VERIFY against supplier COA]
Molecular weight
≈3647.2 g/mol [TO VERIFY against supplier COA]
CAS number
863288-34-0 [TO VERIFY against supplier COA]
Form
Lyophilised powder
Purity
≥99% (see COA)
Format
Lyophilised vial
Vial sizes
2 mg, 5 mg, 10 mg

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

Mechanisms investigated
  • GHRH-receptor agonism [1].
  • Albumin bioconjugation: in rats, the conjugate was present in plasma beyond 72 hours [1].
  • GH pulsatility was preserved during continuous stimulation in healthy adults [3].
Research areas & model types
Research areaModel typeSummary
GRF receptor activation and albumin conjugationIn vitro; rat[1]
GH and IGF-I responsesHuman (healthy adults, randomised placebo-controlled)[2][3]
Human clinical research status
  • Phase 1/2 studies in healthy adults showed sustained increases in GH and IGF-I [2][3]. CJC-1295 is not an approved medicine.
Safety observations reported in studies
  • The healthy-volunteer studies described the compound as relatively well tolerated [2].
Known limitations
  • The human data come only from small, short studies in healthy volunteers.
Storage & handling for laboratory use

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

  • Allow the sealed vial to reach room temperature before opening to limit condensation.
  • Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
  • Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.

Emerging & theoretical

Unconfirmed — hypotheses & ongoing research

These are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.

Hypotheses proposed by researchers

  • Researchers proposed that long-acting GHRH analogues could preserve physiological GH pulsatility, unlike exogenous GH [3].

Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.

References

  1. Jetté L, Léger R, Thibaudeau K et al.. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PubMed 15817669 · doi:10.1210/en.2004-1286
  2. Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683 · doi:10.1210/jc.2005-1536
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PubMed 17018654 · doi:10.1210/jc.2006-1702

Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.

Certificates of analysis

[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]

Open the COA checker

Related research compounds

AOD9604 research peptide vial
Peptide · Lyophilised vial

AOD9604

5 mg · 10 mg
From £37.99View
CJC-1295 (without DAC) research peptide vial
Peptide · Lyophilised vial

CJC-1295 (without DAC)

5 mg · 10 mg
From £23.49View
CJC-1295 (without DAC) / Ipamorelin blend research peptide vial
Peptide blend · Lyophilised vial

CJC-1295 (without DAC) / Ipamorelin blend

10 mg
£34.99View
IGF-1 LR3 research peptide vial
Recombinant protein · Lyophilised vial

IGF-1 LR3

0.1 mg · 1 mg
From £5.99View

Browse similar compounds: Endocrine & receptor-signalling research peptides or the full catalogue.